Echinocandins Versus Azoles for Candidemia Treatment

Candidemia Clinical Trial

— AntiCandiTreat  

Official title:

Echinocandins Versus Azoles as First-line Therapy for the Treatment of Candidemia in Intensive Care Units

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03799172
• Other study ID #: CRC_GHN_2019_001
• Status: Completed
• Start date: November 1, 2018
• Est. completion date: September 1, 2019

Study information

• Verified date: March 2020
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 79
• Est. completion date: September 1, 2019
• Est. primary completion date: February 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles

Exclusion Criteria:

• Patients with neutropenia

• Patients without antifungal treatment

• Patients who received antifungal therapy for more than two days before candidemia diagnosis

• Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy

• Patients who received less than 4 days of antifungal therapy after candidemia diagnosis

Related Conditions & MeSH terms

• Candidemia

Intervention

Drug:
• Echinocandin treatment
Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
• Triazole treatment
Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care. Candidemia was defined as at least one blood culture positive for Candida.

Locations

Country	Name	City	State
France	Hospices Civils de Lyon, Hôpital de la Croix-Rousse	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of all cause hospital mortality on day 90 between echinocandins and azoles	Comparison of all cause hospital mortality on day 90 between echinocandins and azoles	Mortality on day 90 after antifungal initiation
Secondary	Comparison of treatment success on day 30 between echinocandins and azoles.	Treatment success is defined as a complete response if the following two criteria were full-filled: survival and resolution of all attributable symptoms and signs of disease, and mycological success (documented clearance of pathogen from the blood).	Treatment success on day 30 after antifungal initiation